[{"orgOrder":0,"company":"ScinoPharm Taiwan Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Peptide, Unconjugated","year":"2026","type":"Inapplicable","leadProduct":"Glatiramer Acetate","moa":"Polymer","graph1":"Neurology","graph2":"Approved FDF","graph3":"ScinoPharm Taiwan Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ScinoPharm Taiwan Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ScinoPharm Taiwan Ltd \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by ScinoPharm Taiwan Ltd

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmapack
                          Not Confirmed
                          Pharmapack
                          Not Confirmed

                          Details : Glatiramer Acetate, a miscellaneous product targeting polymers, shows promise in treating Multiple Sclerosis (MS).

                          Product Name : Copaxone-Generic

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          January 05, 2026

                          Lead Product(s) : Glatiramer Acetate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank